EBM News English
Leading News Portal in English

Pfizer to allow other companies make its Covid pill, 95 nations to benefit

WASHINGTON NOV 17: US pharmaceutical giant Pfizer has inked an agreement with a UN-backed group to permit other manufacturers to make and supply its experimental Covid-19 pill for use in 95 countries.

The pharma company said it would grant a license for the antiviral pill to Geneva-based Medicines Patent Pool that would allow generic drug firms to produce the pill for use in the 95 countries that make up about 53 per cent of the world’s population. “The agreement will enable MPP to facilitate additional production and distribution of the investigational antiviral, pending regulatory authorization or approval, by granting sub-licenses to qualified generic medicine manufacturers, with the goal of facilitating greater access to the global population,” Pfizer said in a statement. Under the terms of the head license agreement between Pfizer and MPP, qualified generic medicine manufacturers worldwide that are granted sub-licenses will be able to supply PF-07321332 in combination with ritonavir to 95 countries, covering up to approximately 53% of the world’s population. This includes all low- and lower-middle-income countries and some upper-middle-income countries in Sub-Saharan Africa as well as countries that have transitioned from lower-middle to upper-middle-income status in the past five years.
Pfizer will not receive royalties on sales in low-income countries and will further waive royalties on sales in all countries covered by the agreement while COVID-19 remains classified as a Public Health Emergency of International Concern by the World Health Organization. “Pfizer remains committed to bringing forth scientific breakthroughs to help end this pandemic for all people. We believe oral antiviral treatments can play a vital role in reducing the severity of COVID-19 infections, decreasing the strain on our healthcare systems and saving lives,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer.
“We must work to ensure that all people – regardless of where they live or their circumstances – have access to these breakthroughs, and we are pleased to be able to work with MPP to further our commitment to equity.”